Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 22

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
 Average

    Number

    Exercise
        Price

    Remaining
    Life

    Stock
    Warrants

    Outstanding
    December 31, 2023

    —

    $
    —

    —

    Granted

    55,000

    7.50

    4.88

    Expired

    —

    —

    —

    Exercised

    —

    —

    —

    Outstanding
    March 31, 2024

    55,000

    $
    7.50

    4.88

    Exercisable
    March 31, 2024

    55,000

    $
    7.50

    4.88

A
summary of the status of the Company’s nonvested warrants as of March 31, 2025 and 2024, and changes during the three months
ended March 31, 2025 and 2024, is presented below:

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested
    at December 31, 2024

    —

    $
    —

    Granted

    —

    —

    Vested

    —

    —

    Forfeited

    —

    —

    Non-vested
    at March 31, 2025

    —

    $
    —

    Non-vested
    Warrants
     
    Warrants

    Weighted-
    Average
    Exercise
    Price

    Non-vested
    at December 31, 2023

    —

    $
    —

    Granted

    55,000

    7.50

    Vested

    (55,000
    )

    7.50

    Forfeited

    —

    —

    Non-vested
    at March 31, 2024

    —

    $
    —

The
total number of warrants granted during the three months ended March 31, 2025 and 2024 was 0 and 55,000,
respectively. The exercise price for these warrants was $7.50 per share and there was an intrinsic value of $0.

The
Company recognized stock-based compensation expense related to warrant vesting amortization of $0 and $0 for the three months
ended March 31, 2025 and